Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLM031
MIFTS: 58

Poliomyelitis

Categories: Rare diseases, Neuronal diseases, Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Poliomyelitis

About this section

MalaCards integrated aliases for Poliomyelitis:

Name: Poliomyelitis 12 76 53 59 44 15 73
Infantile Paralysis 53 73
Polio 53 55

Characteristics:

Orphanet epidemiological data:

59
poliomyelitis
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Childhood; Age of death: any age;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4953
ICD10 33 A80 A80.9
ICD9CM 35 045 045.9
MeSH 44 D011051
NCIt 50 C35550
Orphanet 59 ORPHA2912
ICD10 via Orphanet 34 A80.4 A80.2 A80.3 more
MESH via Orphanet 45 D011051
UMLS via Orphanet 74 C0032371
Sources

Summaries for Poliomyelitis

About this section
NIH Rare Diseases : 53 Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis. It is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. There are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic. Symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical poliomyelitis to partial or full paralysis. Treatment is aimed at controlling symptoms while the infection runs its course. Since the development of the polio vaccine, the incidence of the disease has been greatly reduced. The prognosis depends on the form of the disease (subclinical, nonparalytic, or paralytic) and the site affected.

MalaCards based summary : Poliomyelitis, also known as infantile paralysis, is related to paralytic poliomyelitis and tetanus. An important gene associated with Poliomyelitis is PVR (Poliovirus Receptor), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Zinc and Phenol have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and b cells, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A viral infectious disease that results in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Wikipedia : 76 Poliomyelitis, often called polio or infantile paralysis, is an infectious disease caused by the... more...

Sources

Related Diseases for Poliomyelitis

About this section

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 294)
# Related Disease Score Top Affiliating Genes
1 paralytic poliomyelitis 32.9 ARHGEF1 DPT PVR
2 tetanus 30.6 IFNG IL10 IL4
3 aseptic meningitis 30.4 IFNG IL10 TNF
4 rubella 30.0 IL10 IL4 TNF
5 meningitis 29.9 FCGR2A IFNG IL10 TNF
6 chlamydia 29.8 IFNG IL10 TNF
7 hemophagocytic lymphohistiocytosis 29.8 IFNG IL10 TNF
8 neuritis 29.8 IFNG IL4 TNF
9 conjunctivitis 29.6 ICAM1 IFNG IL4
10 periodontitis 29.0 IFNG IL10 IL4 TNF
11 myasthenia gravis 29.0 IFNG IL10 IL4 TNF
12 multiple sclerosis 28.6 ICAM1 IFNG IL10 IL4 TNF
13 common variable immunodeficiency 28.1 BTK IFNG IL10 IL4 TNF
14 nonparalytic poliomyelitis 12.4
15 bulbar polio 11.9
16 poliomyelitis in patients with immunodeficiencies deemed at risk 11.9
17 postpoliomyelitis syndrome 11.2
18 spastic diplegia 10.9
19 motor neuron disease 10.9
20 spinal polio 10.9
21 bulbospinal polio 10.9
22 staphylococcal toxic shock syndrome 10.8 IFNG TNF
23 autoimmune myocarditis 10.8 IFNG TNF
24 trichosporonosis 10.8 IFNG TNF
25 chronic beryllium disease 10.8 IFNG TNF
26 crohn's colitis 10.7 IFNG TNF
27 punctate inner choroidopathy 10.7 IL10 TNF
28 meconium aspiration syndrome 10.7 IFNG TNF
29 actinic prurigo 10.7 ICAM1 TNF
30 transient neonatal neutropenia 10.6 FCGR3A FCGR3B
31 soft tissue sarcoma 10.6 IFNG TNF
32 microscopic polyangiitis 10.6 IL10 TNF
33 multifocal choroiditis 10.6 IL10 TNF
34 cytomegalovirus retinitis 10.6 IFNG TNF
35 transient hypogammaglobulinemia 10.6 IL10 TNF
36 rheumatoid vasculitis 10.6 ICAM1 TNF
37 arthus reaction 10.6 ICAM1 TNF
38 spastic paraplegia 32, autosomal recessive 10.6 FCGR3A FCGR3B
39 choroiditis 10.6 IL10 TNF
40 mycoplasmal pneumonia 10.6 IFNG IL4
41 posterior uveitis 10.6 IFNG TNF
42 sporotrichosis 10.6 IFNG IL10
43 idiopathic achalasia 10.6 IL10 TNF
44 trichuriasis 10.6 IL10 TNF
45 mucocutaneous leishmaniasis 10.6 IL10 TNF
46 rheumatic myocarditis 10.5 FCGR3A FCGR3B
47 chronic graft versus host disease 10.5 IFNG IL10
48 tuberculous peritonitis 10.5 IFNG TNF
49 orbital plasma cell granuloma 10.5 FCGR3A FCGR3B
50 pericardial tuberculosis 10.5 IFNG IL10

Graphical network of the top 20 diseases related to Poliomyelitis:



Diseases related to Poliomyelitis
Sources

Symptoms & Phenotypes for Poliomyelitis

About this section

MGI Mouse Phenotypes related to Poliomyelitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 IL10 ARHGEF1 BTK IL4 TNF FCGR2A
2 immune system MP:0005387 9.91 IL10 ARHGEF1 BTK IL4 TNF FCGR2A
3 digestive/alimentary MP:0005381 9.85 IL10 BTK IL4 TNF ICAM1 IFNG
4 integument MP:0010771 9.7 IL10 BTK IL4 DPT TNF ICAM1
5 neoplasm MP:0002006 9.35 IL10 BTK TNF ICAM1 IFNG
6 vision/eye MP:0005391 9.1 IL10 IL4 DPT TNF ICAM1 IFNG
Sources

Drugs & Therapeutics for Poliomyelitis

About this section

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 23994
2
Phenol Approved, Experimental Phase 4 108-95-2 996
3
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
4
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
5
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
6
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
7
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
8
Zinc sulfate Approved, Investigational Phase 4,Not Applicable 7733-02-0
9
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
10
Menthol Approved Phase 4 2216-51-5 16666
11
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 11103-57-4, 68-26-8 445354
12
BCG vaccine Investigational Phase 4,Phase 2,Not Applicable
13 Retinol palmitate Phase 4,Phase 2,Phase 3,Not Applicable
14 Adjuvants, Immunologic Phase 4,Phase 1,Phase 2,Not Applicable
15 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1
17 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
18 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Vitamins Phase 4,Phase 2,Phase 3,Not Applicable
21 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Antibodies, Blocking Phase 4
24 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Antioxidants Phase 4,Phase 2,Phase 3,Not Applicable
26 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
27 Polymyxin B Phase 4
28 Analgesics Phase 4,Phase 3,Phase 2
29 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
30 Chelating Agents Phase 4,Phase 3,Phase 2
31 Cyclooxygenase Inhibitors Phase 4,Phase 2
32 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
33 PENTA Phase 4,Phase 3,Phase 2,Not Applicable
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
35 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anticoagulants Phase 4,Phase 3,Phase 2
37 Polymyxins Phase 4
38 Antidotes Phase 4,Phase 3,Phase 2
39 Iron Chelating Agents Phase 4,Phase 3,Phase 2
40 Anti-Inflammatory Agents Phase 4,Phase 2
41 Antipyretics Phase 4,Phase 3
42 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
43 Antirheumatic Agents Phase 4,Phase 2
44 Calcium, Dietary Phase 4,Phase 3,Phase 2
45 retinol Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable
46 Acidophilus Nutraceutical Phase 4
47 Zinc Supplement Nutraceutical Phase 4,Not Applicable
48
Sulfadoxine Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 2447-57-6 17134
49
Pyrimethamine Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 58-14-0 4993
50
Deferiprone Approved Phase 3 30652-11-0 2972

Interventional clinical trials:

(show top 50) (show all 347)
# Name Status NCT ID Phase Drugs
1 Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine Unknown status NCT01841671 Phase 4
2 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
3 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Unknown status NCT02408926 Phase 4
4 Influence of BCG on TDaP-IPV Vaccination Unknown status NCT02771782 Phase 4
5 Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
6 A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China Completed NCT01278433 Phase 4
7 Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine Completed NCT01475539 Phase 4
8 A Study of the Safety of IMOVAX Polio™ in China Completed NCT01244464 Phase 4
9 A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age Completed NCT02580201 Phase 4
10 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
11 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
12 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
13 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
14 Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines Completed NCT01616693 Phase 4
15 A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania Completed NCT02582255 Phase 4
16 A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children Completed NCT02521974 Phase 4
17 Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine Completed NCT01831050 Phase 4
18 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed NCT00635128 Phase 4
19 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
20 Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules Completed NCT02412514 Phase 4
21 Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine Completed NCT02643368 Phase 4
22 Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia Completed NCT01094171 Phase 4
23 IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi. Completed NCT01695798 Phase 4
24 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
25 Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Completed NCT03147560 Phase 4
26 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
27 Inactivated Influenza Vaccine Effectiveness in Tropical Africa Completed NCT00893906 Phase 4
28 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
29 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
30 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
31 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
32 Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV Completed NCT03310073 Phase 4
33 Direct and Indirect Protection by Influenza Vaccine Given to Children in India Completed NCT00934245 Phase 4
34 Non-Specific Effects of Standard Titre Measles Vaccination Completed NCT00168662 Phase 4
35 Poliovirus Vaccine Trial in Bangladesh Completed NCT01633216 Phase 4
36 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Completed NCT00325156 Phase 4
37 Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
38 Different Doses of Vitamin A and Childhood Morbidity and Mortality Completed NCT00168584 Phase 4 Vitamin A
39 Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course Completed NCT01457547 Phase 4
40 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
41 Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
42 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed NCT00753649 Phase 4
43 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
44 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
45 A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
46 Trial of Two Strains of BCG Completed NCT02447536 Phase 4
47 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Completed NCT01392378 Phase 4 Paracetamol;Ibuprofen;Paracetamol;Ibuprofen
48 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
49 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
50 Influenza Immunization of Children in India Completed NCT01680679 Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Sources

Genetic Tests for Poliomyelitis

About this section
Sources

Anatomical Context for Poliomyelitis

About this section

MalaCards organs/tissues related to Poliomyelitis:

41
Spinal Cord, Brain, B Cells, Liver, Bone, Testes, Lung
Sources

Publications for Poliomyelitis

About this section

Articles related to Poliomyelitis:

(show top 50) (show all 1008)
# Title Authors Year
1
Post-Polio Syndrome and the Late Effects of Poliomyelitis: Part 2. Treatment, Management and Prognosis. ( 29752826 )
2018
2
Total Hip Arthroplasty for Patients with Residual Poliomyelitis at a Mean Eight Years of Follow-up. ( 29674772 )
2018
3
Total hip arthroplasty in patients affected by poliomyelitis. ( 29855245 )
2018
4
Total Hip Arthroplasty for Patients with Residual Poliomyelitis at a Mean Eight Years of Follow-up. ( 29463934 )
2018
5
Technical aspects and complications in the surgical treatment of poliomyelitis-affected lower limb fractures. ( 29605559 )
2018
6
Post-Polio Syndrome and the Late Effects of Poliomyelitis: Part 1. Pathogenesis, Biomechanical Considerations, Diagnosis, and Investigations. ( 29752819 )
2018
7
Vaccine-associated paralytic poliomyelitis in a patient with acute lymphocytic leukemia. ( 29322435 )
2018
8
Good practices and challenges in addressing poliomyelitis and measles in the European Union. ( 29659793 )
2018
9
Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis. ( 29925653 )
2018
10
A Two-Stage Foot Repair in a 55-Year-Old Man with Poliomyelitis. ( 29547029 )
2018
11
Preparedness and response against diseases with epidemic potential in the European Union: a qualitative case study of Middle East Respiratory Syndrome (MERS) and poliomyelitis in five member states. ( 29976185 )
2018
12
Progress Toward Poliomyelitis Eradication - Nigeria, January-December 2017. ( 29494568 )
2018
13
Recipient vaccine-associated paralytic poliomyelitis in China, 2010-2015. ( 29395524 )
2018
14
Progress towards poliomyelitis eradication: Nigeria, Januarya89December 2017. ( 29498497 )
2018
15
On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine. ( 29605427 )
2018
16
Poliomyelitis eradication a89 the review of notifications from the years 2010-2016 sent to National IHR Focal Point ( 28654739 )
2017
17
Progress towards poliomyelitis eradication: Afghanistan, January 2016a89June 2017. ( 28819963 )
2017
18
The push to eradicate poliomyelitis in the Eastern Mediterranean Region. ( 29178113 )
2017
19
A case-control study on the association of pulse oral poliomyelitis vaccination and Gianotti-Crosti syndrome. ( 27943306 )
2017
20
Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016. ( 29240729 )
2017
21
Progress Toward Poliomyelitis Eradication - Pakistan, January 2016-September 2017. ( 29166363 )
2017
22
Vaccine Associated Paralytic Poliomyelitis Unmasking Common Variable Immunodeficiency. ( 28361789 )
2017
23
Negative or positive? The iron lung and poliomyelitis-Zurich, 1951. ( 28675796 )
2017
24
Knowledge assessment regarding poliomyelitis among the caregivers of children who received oral polio vaccine reveals lack of awareness of the vaccine vial monitor (VVM): Implications extending beyond polio eradication. ( 28121284 )
2017
25
Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial. ( 28362135 )
2017
26
Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis. ( 28604777 )
2017
27
Understanding the Dynamics of Poliomyelitis Spread in Pakistan. ( 28845415 )
2017
28
'A matter of commonsense': the Coventry poliomyelitis epidemic 1957 and the British public. ( 29118656 )
2017
29
Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization. ( 28057194 )
2017
30
A systematic review of the worldwide prevalence of survivors of poliomyelitis reported in 31 studies. ( 28694346 )
2017
31
175 Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2017. ( 28387112 )
2017
32
Pathogenic Events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic Poliomyelitis. ( 28356537 )
2017
33
Acute segmental poliomyelitis-like flaccid paralysis in an adult in the UK, associated with enterovirus D68. ( 28626021 )
2017
34
Assessment of energy expenditure in individuals with post-poliomyelitis syndrome. ( 28355321 )
2017
35
Epidemiological Surveillance of Poliomyelitis During the Military and Political Conflict in the Central African Republic, 2013 and 2014. ( 28480271 )
2017
36
Combined tibial lengthening and ankle arthrodesis for patients with certain type of sequelae of poliomyelitis. ( 28117634 )
2017
37
Reverse Less Invasive Stabilization System (LISS) Plating for Proximal Femur Fractures in Poliomyelitis Survivors: A Report of Two Cases. ( 29138386 )
2017
38
Feasibility of using global system for mobile communication (GSM)-based tracking for vaccinators to improve oral poliomyelitis vaccine campaign coverage in rural Pakistan. ( 28802756 )
2017
39
The Destructive Power of Circumstance on Concurrent Poliomyelitis and Osteomyelitis. ( 29051879 )
2017
40
Post-marketing surveillance study to assess the safety and tolerability of an Inactivated Poliomyelitis Vaccine in Indian children. ( 28846490 )
2017
41
Hybrid repair of abdominal aortic aneurysm in a patient with poliomyelitis-related deformities. ( 29242068 )
2017
42
Virologic monitoring of poliovirus type 2 after OPV2 withdrawal in April 2016: an important advance in eradicating poliomyelitis and eliminating live oral poliovirus vaccines worldwide, 2016a892017. ( 28547947 )
2017
43
How Long does Denervation Take in Poliomyelitis? Or is it a Lifetime?&amp;quot; ( 29204007 )
2017
44
Progress Toward Poliomyelitis Eradication - Afghanistan, January 2016-June 2017. ( 28817551 )
2017
45
Progress towards poliomyelitis eradication: Pakistan, January 2016a89September 2017. ( 29171250 )
2017
46
An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia. ( 28549485 )
2017
47
Poliomyelitis and its management in the hospital of Stara Gora, Slovenia (In memoriam Dr Hilda VeliA8kov). ( 29309180 )
2017
48
Morbidity and mortality following poliomyelitis - a lifelong follow-up. ( 27869331 )
2017
49
Poliomyelitis: residual hurdles to global eradication. Commentary. ( 27999213 )
2016
50
A human quadrupedal gait following poliomyelitis: From the Dercum-Muybridge collaboration (1885). ( 26928358 )
2016
Sources

Variations for Poliomyelitis

About this section
Sources

Expression for Poliomyelitis

About this section
Search GEO for disease gene expression data for Poliomyelitis.
Sources

Pathways for Poliomyelitis

About this section

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.85 BTK FCGR2A FCGR3A FCGR3B ICAM1 IFNG
2
TGF-Beta Pathway 64
Show member pathways
 13.38 ARHGEF1 BTK IFNG IL10 IL4 TNF
3
Allograft rejection 1 37
Show member pathways
 12.77 ICAM1 IFNG IL10 IL4 TNF
4
IL-2 Pathway 64
Show member pathways
 12.68 ARHGEF1 BTK IFNG IL4 TNF
5
Influenza A 37
Show member pathways
 12.67 ICAM1 IFNG IL4 TNF
6
Regulation of IFNA signaling 66
Show member pathways
 12.54 IFNG IL10 IL4 TNF
7
NF-kappaB Signaling 4
12.47 BTK IFNG IL10 IL4 PVR TNF
8
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.41 FCGR3A FCGR3B ICAM1 IFNG IL4 TNF
9
Th17 cell differentiation 37
Show member pathways
 12.35 IFNG IL10 IL4 TNF
10
T cell receptor signaling pathway 37
Show member pathways
 12.32 IFNG IL10 IL4 TNF
11
Folate Metabolism 1
Show member pathways
 12.22 ICAM1 IFNG IL4 TNF
12
Th1 Differentiation Pathway 65
Show member pathways
 12.14 IFNG IL10 TNF
13
C-type lectin receptor signaling pathway 37
Show member pathways
 12.1 BTK IL10 TNF
14
Bacterial infections in CF airways 22
Show member pathways
 12.08 IFNG IL4 TNF
15
Phagosome 37
12.04 FCGR2A FCGR3A FCGR3B
16
Fluid shear stress and atherosclerosis 37
11.99 ICAM1 IFNG TNF
17
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.99 BTK ICAM1 IFNG IL10 IL4
18
Tuberculosis 37
11.99 FCGR2A FCGR3A FCGR3B IFNG IL10 TNF
19
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 66
11.98 FCGR3A ICAM1 PVR
20
Fc-GammaR Pathway 64
Show member pathways
 11.96 BTK FCGR2A FCGR3B
21
Platelet activation 37
11.92 ARHGEF1 BTK FCGR2A
22
Spinal Cord Injury 1
11.91 FCGR2A ICAM1 IFNG IL4 TNF
23
Interleukin-4 and 13 signaling 66
11.89 ICAM1 IL10 IL4 TNF
24
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.83 FCGR2A IFNG IL10 IL4 TNF
25
Amoebiasis 37
11.81 IFNG IL10 TNF
26
NF-kappa B signaling pathway 37
11.8 BTK ICAM1 TNF
27
Rheumatoid arthritis 37
11.78 ICAM1 IFNG TNF
28
Glucocorticoid receptor regulatory network 1
11.73 ICAM1 IFNG IL4
29
Innate Lymphoid Cell Differentiation Pathways 65
11.73 IFNG IL10 IL4 TNF
30
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.68 IFNG IL4 TNF
31
Dendritic Cells Developmental Lineage Pathway 65
11.66 IFNG IL10 TNF
32
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.58 ICAM1 IFNG TNF
33
Osteoclast differentiation 37
11.54 BTK FCGR2A FCGR3A FCGR3B IFNG TNF
34
Interleukin-10 signaling 66
11.5 ICAM1 IL10 IL4 TNF
35
Malaria 37
11.49 ICAM1 IFNG IL10 TNF
36
Toxoplasmosis 37
Show member pathways
 11.44 FCGR2A FCGR3A FCGR3B IFNG IL10 IL4
37
Th2 Differentiation Pathway 65
11.42 IFNG IL10 IL4
38
Staphylococcus aureus infection 37
11.3 FCGR2A FCGR3A FCGR3B ICAM1 IL10
39
Development and heterogeneity of the ILC family 1
11.25 IFNG IL4 TNF
40
African trypanosomiasis 37
11.25 ICAM1 IFNG IL10 TNF
41
OX40 Pathway 64
11.14 IFNG IL10 IL4
42
Cytokines and Inflammatory Response 1
11.1 IFNG IL10 IL4 TNF
43
IL1 and megakaryocytes in obesity 1
11.09 ICAM1 IFNG
44
LDL Oxidation in Atherogenesis 64
10.87 ICAM1 TNF
Sources

GO Terms for Poliomyelitis

About this section

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 DPT ICAM1 IFNG IL10 IL4 PVR

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.91 IFNG IL10 IL4 TNF
2 cytokine-mediated signaling pathway GO:0019221 9.84 ICAM1 IL10 IL4 TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.77 BTK ICAM1 TNF
4 cellular response to lipopolysaccharide GO:0071222 9.77 ICAM1 IL10 TNF
5 regulation of immune response GO:0050776 9.73 FCGR3A ICAM1 IL4 PVR
6 response to organic substance GO:0010033 9.72 BTK IL10 TNF
7 positive regulation of cytokine secretion GO:0050715 9.63 IL10 TNF
8 protein import into nucleus, translocation GO:0000060 9.63 IFNG TNF
9 negative regulation of interleukin-6 production GO:0032715 9.62 IL10 TNF
10 positive regulation of protein complex assembly GO:0031334 9.62 IFNG TNF
11 positive regulation of osteoclast differentiation GO:0045672 9.61 IFNG TNF
12 negative regulation of B cell proliferation GO:0030889 9.58 BTK IL10
13 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.58 IFNG TNF
14 negative regulation of growth of symbiont in host GO:0044130 9.57 IL10 TNF
15 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.56 IL10 TNF
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.54 ICAM1 IFNG TNF
17 endothelial cell apoptotic process GO:0072577 9.52 IL10 TNF
18 positive regulation of MHC class II biosynthetic process GO:0045348 9.51 IL10 IL4
19 negative regulation of cytokine secretion involved in immune response GO:0002740 9.49 IL10 TNF
20 type 2 immune response GO:0042092 9.48 IL10 IL4
21 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.46 ICAM1 TNF
22 regulation of isotype switching GO:0045191 9.4 IL10 IL4
23 negative regulation of endothelial cell apoptotic process GO:2000352 9.33 ICAM1 IL10 IL4
24 receptor biosynthetic process GO:0032800 9.32 IL10 TNF
25 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.26 IFNG TNF
26 immune response GO:0006955 9.1 FCGR3A FCGR3B IFNG IL10 IL4 TNF
27 positive regulation of vitamin D biosynthetic process GO:0060557 8.96 IFNG TNF

Molecular functions related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 IFNG IL10 IL4 TNF
2 IgG binding GO:0019864 8.8 FCGR2A FCGR3A FCGR3B
Sources

Sources for Poliomyelitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....